Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Firefly Neuroscience Inc. (NASDAQ:AIFF), an artificial intelligence company advancing precision neuroscience, partnered with NeuroSigma, Inc., a bioelectronic medical device firm, to expand clinician awareness and access to the Monarch eTNS System across the U.S.

Firefly will introduce NeuroSigma’s non-drug pediatric attention-deficit/hyperactivity disorder (ADHD) therapy to psychiatry, neurology, and behavioral health practices utilizing its FDA 510(k)-cleared, AI-powered Evoke platform.

Addressing Pediatric ADHD Care Needs

The collaboration addresses two critical needs in pediatric ADHD care by combining objective brain function insights with a non-medication treatment alternative.

A 2024 study published in the Journal of Clinical Child & Adolescent Psychology revealed that approximately 7.1 million U.S. children have received an ADHD diagnosis.

Notably, nearly one-third of the estimated 6.5 million children with current ADHD receive no specific treatment, as many families actively seek alternatives to traditional stimulant medications.

Integrating AI Analytics And Non-Drug Therapy

Firefly’s Evoke platform combines quantitative electroencephalography and event-related potential testing with AI analytics, leveraging a proprietary database exceeding 200,000 brain scans to deliver objective data on individual brain function.

In March 2026, Firefly identified EEG/ERP biomarkers using Evoke data that may help differentiate among the three ADHD presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined, assisting clinicians in matching appropriate treatments and tracking progress over time.

NeuroSigma’s prescription-only Monarch eTNS System is a palm-sized bioelectronic medical device that delivers mild external trigeminal nerve stimulation via a small forehead patch while a child sleeps.

The FDA cleared the device as a monotherapy for children ages 7 through 12 with ADHD who are not currently taking prescription ADHD drugs.

Commercial Expansion And Partner Roles

NeuroSigma launched U.S. sales for its second-generation Monarch device in July 2026 after building a waitlist of over 1,500 patients, caregivers, and healthcare providers, subsequently expanding third-party installment payment options in September.

AIFF Price Action: Firefly Neuroscience shares were up 42.01% at $1.68 at the time of publication on Friday, according to Benzinga Pro data.

Kateryna Kon via Shutterstock